奥美医疗用品股份有限公司 内部控制审计报告 二○二四年度 信会师报字[2025]第 ZB10617 号 奥美医疗用品股份有限公司全体股东： 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内控审计报告 第 1 页 内部控制审计报告 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了奥美医疗用品股份有限公司（以下简称奥美医疗） 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是奥美医疗董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 立信会计师事务所 中国注册会计师： （特殊普通合伙） 中国注册会计师： 中国•上 ...

奥美医疗用品股份有限公司 关联方占用资金情况专项报告 二○二四年度 关于奥美医疗用品股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZB10618 号 奥美医疗用品股份有限公司全体股东： 我们审计了奥美医疗用品股份有限公司(以下简称"奥美医 疗")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZB10616 号的无保 留意见审计报告。 奥美医疗管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号 ——业务办理》的相关规定编制了后附的 2024 年度非经营性资金占 用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是奥美医疗管理层的责任。 我们将汇总表所载信息与我们审计 ...

Financial Performance - The company's revenue for Q1 2025 was ¥758,656,819.43, representing a 1.64% increase compared to ¥746,413,148.74 in the same period last year[5]. - Net profit attributable to shareholders decreased by 7.86% to ¥86,502,742.68 from ¥93,879,127.79 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥74,064,711.29, down 11.39% from ¥83,581,007.83 in the previous year[5]. - Basic and diluted earnings per share were both ¥0.1366, down 7.83% from ¥0.1482 year-on-year[5]. - The net profit for the current period is 86,652,875.66, a decrease of 7.8% compared to 94,126,734.14 in the previous period[15]. - Operating profit for the current period is 112,646,587.37, down from 115,891,801.50, reflecting a decline of 2.0%[15]. - Total comprehensive income for the current period is 87,303,886.56, compared to 91,049,459.30 in the previous period, reflecting a decrease of 4.0%[15]. - Basic earnings per share for the current period is 0.1366, down from 0.1482 in the previous period, a decline of 10.7%[16]. Assets and Liabilities - The company's total assets increased by 3.33% to ¥5,227,172,701.54 from ¥5,058,919,305.88 at the end of the previous year[5]. - Total assets increased to ¥5,227,172,701.54 from ¥5,058,919,305.88, showing a growth of approximately 3.34%[12]. - Total liabilities rose to ¥1,700,968,927.86 from ¥1,610,882,574.54, indicating an increase of about 5.58%[12]. Cash Flow - The net cash flow from operating activities was ¥187,391,041.57, a slight decrease of 0.21% compared to ¥187,779,958.15 in the same period last year[5]. - Cash flow from operating activities is 187,391,041.57, slightly down from 187,779,958.15, indicating a stable cash generation[16]. - Cash flow from investing activities shows a net inflow of 49,688,746.84, a significant improvement from a net outflow of -39,159,163.55 in the previous period[17]. - Cash flow from financing activities has a net inflow of 63,487,473.60, recovering from a net outflow of -82,168,677.63 in the previous period[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,155[9]. - Major shareholders include Cui Jinhai with 23.02% and Cheng Hong with 15.14% of the shares[9]. Operational Efficiency - The company's net profit margin improved, with net income figures reflecting operational efficiency despite rising costs[14]. - Total operating revenue for the current period reached ¥758,656,819.43, an increase from ¥746,413,148.74 in the previous period, reflecting a growth of approximately 1.67%[14]. - Total operating costs amounted to ¥659,488,618.50, up from ¥644,083,767.68, indicating an increase of about 2.08%[14]. - Research and development expenses rose to ¥29,820,611.27, compared to ¥18,459,891.44 in the previous period, marking a significant increase of approximately 61.5%[14]. Future Plans - The company plans to expand its market presence and invest in new technologies to drive future growth[14].

Financial Performance - The company's operating revenue for 2024 reached ¥3,326,292,089.93, representing a 20.66% increase compared to ¥2,756,665,325.19 in 2023[29]. - Net profit attributable to shareholders for 2024 was ¥368,679,147.09, a significant increase of 233.95% from ¥110,399,864.30 in 2023[29]. - The net profit after deducting non-recurring gains and losses was ¥343,356,546.28, up 122.29% from ¥154,465,339.81 in 2023[29]. - The net cash flow from operating activities increased by 68.04% to ¥711,644,736.40 in 2024 from ¥423,504,615.05 in 2023[29]. - Basic earnings per share for 2024 were ¥0.5899, reflecting a 238.44% increase compared to ¥0.1743 in 2023[29]. - The company's total assets at the end of 2024 were ¥5,058,919,305.88, a slight decrease of 0.50% from ¥5,084,318,038.89 at the end of 2023[29]. - The net assets attributable to shareholders increased by 7.82% to ¥3,436,525,341.34 at the end of 2024 from ¥3,187,229,153.71 at the end of 2023[29]. - The company reported a quarterly revenue of ¥876,216,306.05 in Q4 2024, showing consistent growth throughout the year[33]. Market and Industry Trends - The healthcare industry in China is expected to continue growing due to increased health awareness, aging population, and policy support, with total health expenditure reaching ¥9 trillion in 2023[41]. - The global wound management market is expected to grow from $13 billion in 2017 to $17.8 billion by 2024, with a compound annual growth rate (CAGR) of 4.6%[45]. - The global bandage and medical dressing market was valued at $18.84 billion in 2015 and is projected to reach $24.4 billion by 2020, and $31.3 billion by 2025[46][45]. - China's medical dressing industry has maintained a double-digit growth rate, driven by increasing healthcare resources and rising living standards[51]. - The high-end wound dressing market is projected to reach $6.56 billion by 2024 and $7.779 billion by 2031, reflecting a growing demand for advanced wound care products[56]. - The customized surgical kit market is expected to grow from $8.973 billion in 2017 to $21.347 billion by 2026, with a CAGR of 10.2%[59]. Company Strategy and Positioning - The company is positioned to leverage its high-tech capabilities in the healthcare sector, contributing to economic growth and innovation[41]. - The company is a leading player in the domestic medical dressing industry, focusing on product innovation and process upgrades[62]. - The company focuses on medical consumables, with two main product segments: medical devices and consumer products[66]. - The company aims to increase market penetration through strategic partnerships and potential acquisitions in the medical consumables sector[66]. - The company is committed to maintaining high standards of product safety and efficacy, ensuring compliance with medical regulations[66]. - The company has established a complete industrial chain for medical dressings, infection prevention products, and medical non-woven products, achieving integrated, large-scale, and intelligent production[84]. Product Development and Innovation - Advanced dressing products utilize patented technology for rapid hemostasis, with unique mechanisms that accelerate the physiological coagulation process and reduce blood loss[72]. - The company has developed high-absorbency materials, capable of absorbing up to 30 times their weight in liquid, enhancing healing and reducing the frequency of dressing changes[73]. - The company is developing a new type of carboxymethyl cellulose dressing, aiming to enhance absorption capacity, strength, and biocompatibility, with a goal to apply for at least one patent[111]. - The research on a new biodegradable antibacterial elastic bandage is ongoing, focusing on meeting biocompatibility and biodegradability requirements, with plans to achieve industry standard performance indicators[112]. - The company is working on a medical-grade sodium hyaluronate dressing, which is a key step into the biomedical materials market, targeting to apply for at least one patent and meet industry standards[113]. - The development of a quick-drying reusable medical mask aims to provide a better, eco-friendly, and economical protective option, with plans to achieve industry standard performance indicators[113]. Financial Management and Governance - The company has established a complete and independent governance structure, complying with relevant laws and regulations[149]. - The board of directors consists of 7 members, including 3 independent directors, meeting the requirement of one-third independence[152]. - The company has implemented a comprehensive quality management system, adhering to international standards such as ISO13485 and FDA QSR820, enhancing market confidence[89]. - The company has a dedicated financial department that operates independently and adheres to accounting standards[161]. - The company has established a robust investor relations management system to ensure equal information access for all shareholders[155]. Employee and Compensation Policies - The total number of employees at the end of the reporting period was 4,965, with 3,157 in the parent company and 922 in major subsidiaries[183]. - The company has established a fair and competitive compensation system based on job value and performance assessments[185]. - The total pre-tax compensation for the chairman and president, Cui Jinhai, is 5.49 million yuan[174]. - The total pre-tax compensation for the vice chairman, Cheng Hong, is 3.45 million yuan[174]. - The company regularly reviews its compensation and incentive systems to maintain effectiveness[172]. Risk Factors - The company reported a significant reliance on foreign sales, particularly in North America and Europe, which poses risks due to export policies and economic conditions in these regions[9]. - Raw material costs, primarily cotton, constitute a large portion of the company's main business costs, making it vulnerable to price fluctuations in commodities[10]. - The company has a substantial portion of its sales revenue in foreign currencies, particularly USD, which exposes it to exchange rate fluctuations that could impact gross margins and operating performance[11].

奥美医疗（002950）公告，2025年第一季度营收为7.59亿元，同比增长1.64%；净利润为8650.27万元， 同比下降7.86%。 ...

奥美医疗（002950）公告，2024年营业收入33.26亿元，同比增长20.66%。归属于上市公司股东的净利 润3.69亿元，同比增长233.95%。基本每股收益0.5899元/股，同比增长238.44%。公司拟向全体股东每10 股派发现金红利0.6元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

4月14日，奥美医疗今日收盘8.19元，上涨2.12%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到23.03倍，总市值51.86亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.71倍，行业中值29.99倍，奥美医疗排 名第54位。 股东方面，截至2024年9月30日，奥美医疗股东户数41703户，较上次减少343户，户均持股市值35.28万 元，户均持股数量2.76万股。 奥美医疗用品股份有限公司的主营业务为医用耗材及一次性医疗器械、感染防护用品、家庭护理产品的 研发、生产和销售。主要产品为纱布片、无纺布片、不粘伤口片等。公司是行业内少数拥有完整产业 链,且自动化水平较高的企业之一。在二十余年的发展历程中,公司积累了丰富的行业经验及生产经验,目 前公司是我国医用敷料行业领先的生产商和出口商,拥有多个生产基地,配备先进的生产设备,规模化生产 程度较高。2022年11月，奥美医疗名列"2022湖北民营企业制造业100强榜单"。2023年11月，奥美医疗 再度荣列工信部2022年中国医药工业百强榜单，较上一次提升8名；2023年12月，奥美医疗"医用敷料智 能制造示范工厂项目" ...

股东方面，截至2024年9月30日，奥美医疗股东户数41703户，较上次减少343户，户均持股市值35.28万 元，户均持股数量2.76万股。 奥美医疗用品股份有限公司的主营业务为医用耗材及一次性医疗器械、感染防护用品、家庭护理产品的 研发、生产和销售。主要产品为纱布片、无纺布片、不粘伤口片等。公司是行业内少数拥有完整产业 链,且自动化水平较高的企业之一。在二十余年的发展历程中,公司积累了丰富的行业经验及生产经验,目 前公司是我国医用敷料行业领先的生产商和出口商,拥有多个生产基地,配备先进的生产设备,规模化生产 程度较高。2022年11月，奥美医疗名列"2022湖北民营企业制造业100强榜单"。2023年11月，奥美医疗 再度荣列工信部2022年中国医药工业百强榜单，较上一次提升8名；2023年12月，奥美医疗"医用敷料智 能制造示范工厂项目"获评工信部"年度智能制造示范工厂"揭榜单位。 4月10日，奥美医疗今日收盘8.0元，上涨1.91%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到22.50倍，总市值50.66亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.15倍，行业 ...

截至2025年4月1日收盘，奥美医疗(002950)报收于9.23元，上涨3.82%，换手率1.82%，成交量8.2万手， 成交额7545.6万元。 当日关注点 交易信息汇总 当日主力资金净流入411.22万元，占总成交额5.45%；游资资金净流出282.58万元，占总成交额3.75%； 散户资金净流出128.64万元，占总成交额1.7%。 公司公告汇总 奥美医疗用品股份有限公司董事会于2025年1月20日召开第三届董事会第十二次会议，审议通过了关于 以集中竞价交易方式回购公司股份方案的议案，同意公司以自有资金及股票回购专项贷款资金通过集中 竞价交易方式回购公司股份，用于股权激励或员工持股计划。回购价格不超过11.00元/股，回购资金总 额不低于5,000万元且不超过10,000万元，回购期限为自董事会审议通过之日起12个月内。截至2025年3 月31日，公司累计通过深圳证券交易所交易系统以集中竞价交易方式回购公司股份1,018,300股，占公司 总股本的0.1608%，最高成交价为9.15元/股，最低成交价为8.79元/股，支付总金额为9,135,899.00元。公 司后续将根据市场情况在回购期限内继续实施 ...

一、股份回购实施进展 截至 2025 年 3 月 31 日，公司累计通过深圳证券交易所交易系统以集中竞价交易方式 回购公司股份 1,018,300 股，占公司目前总股本的比例为 0.1608%，最高成交价为 9.15元 /股，最低成交价为 8.79 元/股，支付的总金额为 9,135,899.00 元（不含印花税、交易佣金 等交易费用）。 二、其他说明 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场情况 在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露义务。敬 请广大投资者关注后续公告，并注意投资风险。 特此公告。 证券代码：002950 证券简称：奥美医疗 公告编号：2025-011 奥美医疗用品股份有限公司 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方 ...